Literature DB >> 23242719

Fertility-sparing treatment of endometrial cancer precursors among young women: a reproductive point of view.

E Ricciardi1, P Maniglio, A Frega, R Marci, D Caserta, M Moscarini.   

Abstract

BACKGROUND: Early-stage endometrial cancer and complex atypical hyperplasia are treated with hysterectomy and bilateral salpingo-oophorectomy. An emerging issue among younger women affected is the possibility of a fertility-sparing treatment with progestative therapy and close follow-up. AIM: To assess the possibility of conceiving after a diagnosis of atypical endometrial hyperplasia among women younger than 40 years old, in term of delaying definitive treatment and achieving pregnancy.
MATERIALS AND METHODS: 15 women younger than 40 years old with complex CAH or early carcinoma of the endometrium and a wish to preserve fertility. Progestins were administered orally for at least a 12 weeks period. Endometrial biopsies were used at follow-up.
RESULTS: In 11 women, a complete pathological remission of the disease was observed. 4 pregnancies were attained in 4 women. 3 showed progression and underwent definitive surgery at 18 months. 1 showed no response at 24 months and 3 cycles and was counseled to receive a hysterectomy.
CONCLUSIONS: A conservative approach in patients younger than 40 years appears a valid option, and a progestative therapy trial should be attempted whether a valid consensus is attained. Considering the risk to find AEH at biopsies and eventually a carcinoma at hysterectomy (25% of cases) a careful management is strictly required.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23242719

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  5 in total

1.  The effect of assisted reproductive technologies on gynecological cancer: report of our experiences and literature review.

Authors:  Mojgan Karimi Zarchi; Mitra Rouhi; Alime H Abdolahi; Seyedhossein Hekmatimoghaddam
Journal:  Int J Biomed Sci       Date:  2013-09

2.  Conservative therapy with metformin plus megestrol acetate for endometrial atypical hyperplasia.

Authors:  Weiwei Shan; Chao Wang; Zhenbo Zhang; Chao Gu; Chengcheng Ning; Xuezhen Luo; Qiongjie Zhou; Xiaojun Chen
Journal:  J Gynecol Oncol       Date:  2014-07-03       Impact factor: 4.401

Review 3.  Comparison among fertility-sparing therapies for well differentiated early-stage endometrial carcinoma and complex atypical hyperplasia.

Authors:  Qing Zhang; Gonghua Qi; Margaux J Kanis; Ruifen Dong; Baoxia Cui; Xingsheng Yang; Beihua Kong
Journal:  Oncotarget       Date:  2017-05-03

4.  Overexpression of erythropoietin-producing hepatocyte receptor B4 and ephrin-B2 is associated with estrogen receptor expression in endometrial adenocarcinoma.

Authors:  Ling-Dan Dong; Xiang-Lin Cheng; Long Zhou; Qing Huang; Jun-Chuan Li; Cun-Jian Yi
Journal:  Oncol Lett       Date:  2017-02-08       Impact factor: 2.967

5.  Weight control is vital for patients with early-stage endometrial cancer or complex atypical hyperplasia who have received progestin therapy to spare fertility: a systematic review and meta-analysis.

Authors:  Miaomiao Li; Tao Guo; Ran Cui; Ying Feng; Huimin Bai; Zhenyu Zhang
Journal:  Cancer Manag Res       Date:  2019-05-06       Impact factor: 3.602

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.